Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENVB Enveric Biosciences	$1.22 +5.0%	$1.23	$1.01 ▼ $8.45	$3.77M	0.46	81,868 shs	64,424 shs
HEPA Hepion Pharmaceuticals	$0.05 -4.5%	$0.06	$0.03 ▼ $0.08	$491K	1.52	85,745 shs	79,733 shs
LIPO Lipella Pharmaceuticals	$0.59 -1.2%	$0.89	$0.55 ▼ $7.31	$2.64M	-0.1	879,551 shs	1,098 shs
PCSA Heatwurx	$0.22 +5.3%	$0.23	$0.15 ▼ $1.52	$10.42M	1.32	5.33 million shs	6.42 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENVB Enveric Biosciences	+5.01%	+10.91%	-10.95%	-4.69%	-85.22%
HEPA Hepion Pharmaceuticals	-4.52%	-12.86%	-14.22%	-28.33%	-99.86%
LIPO Lipella Pharmaceuticals	-1.22%	-6.32%	-15.81%	-79.65%	-83.31%
PCSA Heatwurx	+5.31%	+0.88%	-9.36%	-9.05%	-85.75%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ENVB Enveric Biosciences	1.5082 of 5 stars	3.5	2.0	0.0	0.0	0.6	0.0	0.6
HEPA Hepion Pharmaceuticals	0.5907 of 5 stars	0.0	5.0	0.0	0.0	0.6	0.0	0.6
LIPO Lipella Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PCSA Heatwurx	2.9706 of 5 stars	3.5	4.0	0.0	0.0	2.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ENVB Enveric Biosciences	3.00	Buy	$10.00	719.67% Upside
HEPA Hepion Pharmaceuticals	0.00	N/A	N/A	N/A
LIPO Lipella Pharmaceuticals	0.00	N/A	N/A	N/A
PCSA Heatwurx	3.00	Buy	$2.00	817.43% Upside

Current Analyst Ratings Breakdown

Latest HEPA, PCSA, ENVB, and LIPO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/30/2025	PCSA Heatwurx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $2.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ENVB Enveric Biosciences	N/A	N/A	N/A	N/A	$0.67 per share	N/A
HEPA Hepion Pharmaceuticals	N/A	N/A	N/A	N/A	$1.29 per share	N/A
LIPO Lipella Pharmaceuticals	$536.36K	4.92	N/A	N/A	$1.59 per share	0.37
PCSA Heatwurx	N/A	N/A	N/A	N/A	$0.12 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ENVB Enveric Biosciences	-$9.57M	-$38.38	N/A	N/A	N/A	N/A	-341.48%	-240.71%	N/A
HEPA Hepion Pharmaceuticals	-$48.93M	-$219.00	N/A	∞	N/A	N/A	-812.56%	-207.31%	N/A
LIPO Lipella Pharmaceuticals	-$5.02M	-$3.43	N/A	∞	N/A	-988.83%	-224.08%	-172.88%	N/A
PCSA Heatwurx	-$11.85M	-$2.32	N/A	N/A	N/A	N/A	-342.36%	-243.48%	10/29/2025 (Estimated)

Latest HEPA, PCSA, ENVB, and LIPO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2025	Q2 2025	ENVB Enveric Biosciences	-$5.25	-$0.97	+$4.28	-$0.97	N/A	N/A
8/7/2025	Q2 2025	PCSA Heatwurx	-$0.23	-$0.25	-$0.02	-$0.25	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ENVB Enveric Biosciences	N/A	N/A	N/A	N/A	N/A
HEPA Hepion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LIPO Lipella Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PCSA Heatwurx	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ENVB Enveric Biosciences	N/A	2.42	4.08
HEPA Hepion Pharmaceuticals	N/A	1.30	1.30
LIPO Lipella Pharmaceuticals	N/A	6.21	6.21
PCSA Heatwurx	N/A	3.45	3.45

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ENVB Enveric Biosciences	13.82%
HEPA Hepion Pharmaceuticals	17.24%
LIPO Lipella Pharmaceuticals	74.31%
PCSA Heatwurx	91.93%

Insider Ownership

Company	Insider Ownership
ENVB Enveric Biosciences	1.10%
HEPA Hepion Pharmaceuticals	0.06%
LIPO Lipella Pharmaceuticals	32.11%
PCSA Heatwurx	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ENVB Enveric Biosciences	20	3.25 million	3.21 million	Not Optionable
HEPA Hepion Pharmaceuticals	20	11.44 million	6.63 million	No Data
LIPO Lipella Pharmaceuticals	4	4.47 million	3.03 million	Not Optionable
PCSA Heatwurx	20	50.35 million	49.14 million	Not Optionable

HEPA, PCSA, ENVB, and LIPO Headlines

Recent News About These Companies

Heatwurx (NASDAQ:PCSA) Shares Down 3.4% - Here's What Happened

August 15, 2025 | americanbankingnews.com

Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies

August 7, 2025 | globenewswire.com

Processa Pharmaceuticals Provides Portfolio and Business Update

July 1, 2025 | globenewswire.com

Processa Pares Gains on Equity Offer News

June 17, 2025 | marketwatch.com

Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering

June 17, 2025 | globenewswire.com

Processa Pharmaceuticals Enters Exclusive Licensing Agreement with Intact Therapeutics for PCS12852, Potential Treatment for Gastroparesis

June 17, 2025 | quiverquant.comQ

Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate

June 17, 2025 | globenewswire.com

Processa Pharmaceuticals to Showcase Next Generation Cancer Therapies at 2025 BIO International Convention

June 15, 2025 | nasdaq.com

Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025

June 13, 2025 | globenewswire.com

Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting

May 30, 2025 | globenewswire.com

Processa Pharmaceuticals’ Dr. David Young to Present at World Orphan Drug Congress USA 2025

April 15, 2025 | markets.businessinsider.com

Processa Pharmaceuticals' Dr. David Young to Present at World Orphan Drug Congress USA 2025

April 15, 2025 | globenewswire.com

Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference

March 18, 2025 | globenewswire.com

Processa Pharmaceuticals, Inc. (PCSA): Among the Cheapest Stocks Insiders Are Buying Recently

February 21, 2025 | insidermonkey.com

Processa Pharmaceuticals faces Nasdaq delisting risk over share price

February 10, 2025 | msn.com

Favourable Signals For Processa Pharmaceuticals: Numerous Insiders Acquired Stock

February 7, 2025 | finance.yahoo.com

Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference

February 7, 2025 | globenewswire.com

Processa Pharmaceuticals Closes $5 Million Public Offering with CEO and Institutional Investor Participation

January 30, 2025 | quiverquant.comQ

Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

January 30, 2025 | globenewswire.com

Processa Pharmaceuticals director David Young buys $99,288 in stock

January 30, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HEPA, PCSA, ENVB, and LIPO Company Descriptions

Enveric Biosciences NASDAQ:ENVB

$1.22 +0.06 (+5.01%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.18 -0.03 (-2.87%)

As of 08/22/2025 07:31 PM Eastern

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Hepion Pharmaceuticals NASDAQ:HEPA

$0.05 0.00 (-4.52%)

As of 08/22/2025 02:15 PM Eastern

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

Lipella Pharmaceuticals NASDAQ:LIPO

$0.59 -0.01 (-1.22%)

As of 08/22/2025 02:47 PM Eastern

Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.

Heatwurx NASDAQ:PCSA

$0.22 +0.01 (+5.31%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$0.22 +0.00 (+0.46%)

As of 08/22/2025 07:59 PM Eastern

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time